Literature DB >> 18444914

Hematopoietic stem cell engraftment and seeding permits multi-lymphoid chimerism in vascularized bone marrow transplants.

M Siemionow1, A Klimczak, S Unal, G Agaoglu, K Carnevale.   

Abstract

Vascularized bone marrow transplantation (VBMT) across a MHC barrier under a 7-day alphabeta-TCR mAb and CsA protocol facilitated multiple hematolymphoid chimerism via trafficking of the immature (CD90) bone marrow cells (BMC) between donor and recipient compartments. Early engraftment of donor BMC [BN(RT1(n))] into the recipient BM compartment [LEW(RT1(l))] was achieved at 1 week posttransplant and this was associated with active hematopoiesis within allografted bone and correlated with high chimerism in the hematolymphoid organs. Two-way trafficking between donor and recipient BM compartments was confirmed by the presence of recipient MHC class I cells (RT1(l)) within the allografted bone up to 3 weeks posttransplant. At 10 weeks posttransplant, decline of BMC viability in allografted bone corresponded with bone fibrosis and lack of hematopoiesis. In contrast, active hematopoiesis was present in the recipient bone as evidenced by the presence of donor-specific immature (CD90/RT1(n)) cells, which correlated with chimerism maintenance. Clonogenic activity of donor-origin cells (RT1(n)) engrafted into the host BM compartment was confirmed by colony-forming units (CFU) assay. These results confirm that hematolymphoid chimerism is developed early post-VBMT by T-cell lineage and despite allografted bone fibrosis chimerism maintenance is supported by B-cell linage and active hematopoiesis of donor-origin cells in the host BM compartment.

Entities:  

Mesh:

Year:  2008        PMID: 18444914     DOI: 10.1111/j.1600-6143.2008.02241.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  10 in total

1.  Vascularized composite allotransplantation combined with costimulation blockade induces mixed chimerism and reveals intrinsic tolerogenic potential.

Authors:  Byoung Chol Oh; Georg J Furtmüller; Madeline L Fryer; Yinan Guo; Franka Messner; Johanna Krapf; Stefan Schneeberger; Damon S Cooney; W P Andrew Lee; Giorgio Raimondi; Gerald Brandacher
Journal:  JCI Insight       Date:  2020-04-09

2.  Dissociation between peripheral blood chimerism and tolerance to hindlimb composite tissue transplants: preferential localization of chimerism in donor bone.

Authors:  Dina N Rahhal; Hong Xu; Wei-Chao Huang; Shengli Wu; Yujie Wen; Yiming Huang; Suzanne T Ildstad
Journal:  Transplantation       Date:  2009-09-27       Impact factor: 4.939

3.  Upper-extremity transplantation using a cell-based protocol to minimize immunosuppression.

Authors:  Stefan Schneeberger; Vijay S Gorantla; Gerald Brandacher; Adriana Zeevi; Anthony J Demetris; John G Lunz; Diana M Metes; Albert D Donnenberg; Jaimie T Shores; Andrea F Dimartini; Joseph E Kiss; Joseph E Imbriglia; Kodi Azari; Robert J Goitz; Ernest K Manders; Vu T Nguyen; Damon S Cooney; Galen S Wachtman; Jonathan D Keith; Derek R Fletcher; Camila Macedo; Raymond Planinsic; Joseph E Losee; Ron Shapiro; Thomas E Starzl; W P Andrew Lee
Journal:  Ann Surg       Date:  2013-02       Impact factor: 12.969

4.  Donor Recipient Chimeric Cells Induce Chimerism and Extend Survival of Vascularized Composite Allografts.

Authors:  Joanna Cwykiel; Arkadiusz Jundzill; Aleksandra Klimczak; Maria Madajka-Niemeyer; Maria Siemionow
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2021-05-10       Impact factor: 4.291

5.  Creation of Dystrophin Expressing Chimeric Cells of Myoblast Origin as a Novel Stem Cell Based Therapy for Duchenne Muscular Dystrophy.

Authors:  M Siemionow; J Cwykiel; A Heydemann; J Garcia-Martinez; K Siemionow; E Szilagyi
Journal:  Stem Cell Rev Rep       Date:  2018-04       Impact factor: 5.739

6.  The Positive Impact of Donor Bone Marrow Cells Transplantation into Immunoprivileged Compartments on the Survival of Vascularized Skin Allografts.

Authors:  Arkadiusz Jundziłł; Aleksandra Klimczak; Erhan Sonmez; Grzegorz Brzezicki; Maria Siemionow
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2021-10-11       Impact factor: 4.291

Review 7.  Improving the safety of tolerance induction: chimerism and cellular co-treatment strategies applied to vascularized composite allografts.

Authors:  Wei-Chao Huang; Jeng-Yee Lin; Christopher Glenn Wallace; Fu-Chan Wei; Shuen-Kuei Liao
Journal:  Clin Dev Immunol       Date:  2012-10-22

8.  Chimerism-based experimental models for tolerance induction in vascularized composite allografts: Cleveland clinic research experience.

Authors:  Maria Siemionow; Aleksandra Klimczak
Journal:  Clin Dev Immunol       Date:  2013-03-14

Review 9.  The need for inducing tolerance in vascularized composite allotransplantation.

Authors:  Kadiyala V Ravindra; Hong Xu; Larry D Bozulic; David D Song; Suzanne T Ildstad
Journal:  Clin Dev Immunol       Date:  2012-10-31

10.  Dystrophin Expressing Chimeric (DEC) Human Cells Provide a Potential Therapy for Duchenne Muscular Dystrophy.

Authors:  Maria Siemionow; Joanna Cwykiel; Ahlke Heydemann; Jesus Garcia; Enza Marchese; Krzysztof Siemionow; Erzsebet Szilagyi
Journal:  Stem Cell Rev Rep       Date:  2018-06       Impact factor: 5.739

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.